<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00414687</url>
  </required_header>
  <id_info>
    <org_study_id>90427</org_study_id>
    <secondary_id>300341</secondary_id>
    <nct_id>NCT00414687</nct_id>
  </id_info>
  <brief_title>Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension</brief_title>
  <official_title>An Explorative, Open-Label, Multicenter, Randomized, Parallel-Group Comparative Study of Safety, Tolerability, and the Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension Over 2 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the study drug is effective in the
      long-term treatment of primary or secondary pulmonary hypertension
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been
      renamed to Bayer Schering Pharma AG, Germany.

      Bayer Schering Pharma AG, Germany is the sponsor of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <completion_date type="Actual">May 2001</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability: Adverse events (AE) and safety variables, Variables to describe clinical effects: NYHA class, Walking distance (6-min walk), Mahler Dyspnea Index, EuroQoL, Karnofsky Index, Hemodynamic and gas exchange</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality and lung/heart-lung transplantation, Acute effects of iloprost inhalation on hemodynamics and gas exchange</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall clinical tolerability of the long-term use of iloprost aerosol</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events and deaths</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of long-term administration of inhaled iloprost on mortality and transplantation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute effect of inhaled iloprost on hemodynamics and gas exchange</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of long-term administration of inhaled iloprost on hemodynamics and gas exchange</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ventavis (Iloprost, BAYQ6256)</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients

          -  Secondary pulmonary hypertension

          -  Mean pulmonary artery pressure equal or above 40 mmHg or primary pulmonary
             hypertension with a pressure equal or above 30 mmHg while resting during appropriate
             conventional treatment

          -  Written informed consent after having been duly informed about all diagnostic and
             therapeutic measures involved in the study

        Exclusion Criteria:

          -  Clinical Instability at baseline

          -  Pulmonary venous obstruction

          -  Global respiratory insufficiency

          -  Obstructive ventilation disorders, Interstitial pulmonary disease

          -  Cerebrovascular events

          -  Myocardial infarction or major cardiac surgery within 3 months prior to baseline

          -  Bleeding disorders or bleeding risk

          -  Severe hepatic insufficiency or renal insufficiency

          -  Malignant diseases

          -  HIV positive

          -  Pregnancy, female patients of child-bearing potential without adequate contraception
             and nursing mothers

          -  Congenital or acquired valvular defects and myocardial function disorders not related
             to pulmonary hypertension

          -  Prior pulmonary embolism

          -  Collagenosis

          -  Pulmonary arterial or valvular stenosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product</description>
  </link>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2006</study_first_submitted>
  <study_first_submitted_qc>December 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2006</study_first_posted>
  <last_update_submitted>May 14, 2009</last_update_submitted>
  <last_update_submitted_qc>May 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Therapeutic Area Head</name_title>
    <organization>Bayer Schering Pharma AG</organization>
  </responsible_party>
  <keyword>Primary or secondary Pulmonary hypertension</keyword>
  <keyword>Iloprost</keyword>
  <keyword>Inhaled</keyword>
  <keyword>Long-term treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

